Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis

BackgroundThe optimal first-line immune checkpoint inhibitor (ICI) treatment strategy for metastatic or early triple-negative breast cancer (TNBC) has not yet been determined as a result of various randomized controlled trials (RCTs). The purpose of this study was to compare the efficacy and safety...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2023-05-01
Sarja:	Frontiers in Endocrinology
Aiheet:	immune checkpoint inhibitors atezolizumab pembrolizumab durvalumab triple-negative breast cancer network meta-analysis
Linkit:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1137464/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!